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e have identiﬁed a new pathway of ER-associated
 
degradation in 
 
Saccharomyces cerevisiae
 
 that
functions separately from the 
 
HRD
 
/
 
DER
 
 pathway
comprised of Hrd1p, Hrd3p, Der1p, and Ubc7p. This path-
 
way, termed Hrd1p independent-proteolysis (HIP), is capable
of recognizing and degrading both lumenal (CPY* and
PrA*), and integral membrane proteins (Sec61–2p) that
misfold in the ER. CPY* overexpression likely saturates the
 
HRD
 
/
 
DER
 
 pathway and activates the HIP pathway, so the
 
slowed degradation kinetics of CPY* in a 
 
hrd1
 
 
 
 strain is
restored to a wild-type rate when CPY* is overexpressed.
W
 
Substrates of HIP require vesicular trafﬁcking between the
ER and Golgi apparatus before degradation by the ubiquitin-
proteasome system. Ubiquitination of HIP substrates does
not involve the 
 
HRD
 
/
 
DER
 
 pathway ubiquitin ligase Hrd1p,
but instead uses another ubiquitin ligase, Rsp5p. HIP is
regulated by the unfolded protein response as Ire1p is
necessary for the degradation of CPY* when overexpressed,
but not when CPY* is expressed at normal levels. Both the
HIP and 
 
HRD
 
/
 
DER
 
 pathways contribute to the degradation
of CPY*, and only by eliminating both is CPY* degradation
completely blocked.
 
Introduction
 
The highly conserved eukaryotic secretory pathway initiates
at the ER, where proteins enter through the Sec61p-mediated
 
translocon in an unfolded state (Deshaies et al., 1991). In the
lumen of the ER, proteins undergo folding and maturation
involving glycosylation, disulfide bond formation, and
oligomerization. Before exiting the ER, proteins must first
pass an ER quality control (ERQC)* system that ensures
correct folding and processing has transpired (Brodsky and
McCracken, 1999; Ellgaard et al., 1999). Failure to pass this
quality control checkpoint results in the protein’s degrada-
tion, preventing any toxic consequences that may result from
an accumulation of aberrant proteins in the secretory pathway
(Kopito, 1997; Plemper and Wolf, 1999). Quality control
within the secretory pathway involves ER retention, ER-
associated degradation (ERAD) and potential retrieval from
downstream organelles (Ellgaard et al., 1999). ERQC uses
molecular chaperones (Brodsky et al., 1999) and glycosylation
events (Hebert et al., 1995; Jakob et al., 1998) to recognize
misfolded or unassembled proteins. Such proteins are ex-
ported from the ER to the cytosol via the translocon and are
degraded. The most well-characterized facet of ERAD occurs
in yeast and utilizes the 
 
HRD
 
/
 
DER
 
 pathway (Wilhovsky et
al., 2000) or HRD complex (Gardner et al., 2000). The
 
HRD
 
/
 
DER
 
 pathway consists of Hrd1p/Der3p, Hrd3p,
Der1p, and the ubiquitin-conjugating enzymes Ubc7p and
Ubc1p, which together act to deliver misfolded proteins to
the proteasome (Hampton et al., 1996; Knop et al., 1996;
Bordallo et al., 1998; Friedlander et al., 2000). Hrd1p/Der3p,
an ER-integral membrane protein, is the E3-ubiquitin ligase
whose cytosolically positioned RING-H2 domain mediates
the specific covalent attachment of ubiquitin to the target sub-
strates (Bays et al., 2001; Deak and Wolf, 2001). Hrd3p regu-
lates Hrd1p (Gardner et al., 2000), whereas the function of
Der1p remains unknown (Knop et al., 1996).
ERQC contributes to the manifestation of a number of
diseases by either depleting cells of essential proteins, or by the
accumulation and aggregation of misfolded/mutant proteins
it is incapable of degrading. Such substrates include the
following: CFTR-
 
 
 
F508 (Ward et al., 1995), 
 
 
 
1-antitrypsin
inhibitor (Teckman and Perlmutter, 1996), unassembled T
cell receptor subunits (Bonifacino et al., 1989), and apoB
under conditions of limited lipid availability (Fisher et al.,
1997). Pathogens are able to promote or conceal their infection
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by manipulating the ERQC system to degrade CD4 or
MHC class I heavy chain molecules (Margottin et al., 1996;
Wiertz et al., 1996), whereas bacterial toxins usurp ERQC
to access cytosolic targets (Simpson et al., 1999). ERQC
substrates characterized in yeast include CPY* and PrA*,
which are mutant forms of the yeast vacuolar carboxypepti-
dase Y (CPY) and proteinase A (PrA), respectively, that are
retained in the ER (Knop et al., 1996), and Sec61–2p,
which is a mutant subunit of the translocon (Biederer et al.,
1996). Finally, the ERQC-degradative machinery also acts
in a regulatory role to moderate the half-life of correctly
folded proteins such as HMG-CoA reductase in response to
cellular signals so as to modulate the sterol-synthesizing me-
valonate pathway (Hampton et al., 1996).
The ERQC is intimately associated with the unfolded pro-
tein response (UPR), a wide-ranging cellular response to
transcriptionally up-regulate a number of distinct mecha-
nisms to cope with the ER stress encountered when increased
amounts of misfolded proteins accumulate in the ER (Fried-
lander et al., 2000). ER stress is thought to be sensed by
Ire1p and the chaperone Kar2p, which transduce the UPR
signal from the ER to the nucleus where in yeast almost 400
genes are transcriptionally up-regulated, including those en-
coding molecular chaperones, components of the 
 
HRD
 
/
 
DER
 
pathway, and machinery responsible for vesicular transport
between the ER and Golgi apparatus (Travers et al., 2000).
The 
 
HRD
 
/
 
DER
 
 pathway is able to target a number of
ERQC substrates for proteasomal degradation, yet CPY*
turnover, while impaired in 
 
HRD
 
/
 
DER
 
-deficient strains, still
proceeds at a substantial rate (Hill and Cooper, 2000). This
slowed, but not abolished, degradation in the absence of
Hrd1p is also the case for a number of other substrates (Wil-
hovsky et al., 2000). Furthermore, the inactivation of the
 
HRD
 
/
 
DER
 
 pathway has no effect on the degradation of unas-
sembled Vph1p (Hill and Cooper, 2000) and Fur4–430Np
(Wilhovsky et al., 2000). This 
 
HRD
 
/
 
DER
 
-independent means
of degradation prompted the prediction of an additional deg-
radative pathway (Hill and Cooper, 2000), or at a minimum
an additional ubiquitin ligase (Wilhovsky et al., 2000).
Our interest in such an alternative degradative pathway re-
sulted in the discovery of the requirement of ER-Golgi trans-
port for efficient degradation of ERQC substrates (Caldwell et
al., 2001). Inactivation of Sec12p (required for vesicle to exit
the ER) or Sec18p (vesicle fusion with a post-ER compartment)
significantly slowed the degradative rate of CPY* as did the ab-
sence of Erv29p (Caldwell et al., 2001). Erv29p is localized to
the ER and Golgi apparatus, contains an ER-retrieval sequence,
and behaves as a cargo loading/transport receptor that acts to
transport a subset of lumenal proteins including CPY and PrA
from the ER to the Golgi apparatus via COPII-coated vesicles
(Belden and Barlowe, 2001; Caldwell et al., 2001). The absence
of Erv29p severely retards the ER-Golgi transport of such
ligands, yet the secretory pathway remains functional with in-
vertase and alkaline phosphatase displaying normal transport ki-
netics (Caldwell et al., 2001). It is likely that CPY* also requires
Erv29p to enter such transport vesicles and therefore, the ab-
sence of Erv29p severely impairs the transport of CPY* from
the ER to the Golgi apparatus. This work investigates the role
ER-Golgi trafficking plays in ERQC and resulted in the identi-
fication of an 
 
HRD
 
/
 
DER
 
-independent ERQC mechanism ca-
 
pable of recognizing both lumenal and integral membrane
substrates in the yeast 
 
Saccharomyces cerevisiae
 
. This separate
degradative mechanism requires ER-Golgi transport as evi-
denced by the requirement of Erv29p and Sec12p. We were
able to directly observe this novel degradative mechanism by
overexpressing CPY* because under these conditions the 
 
HRD
 
/
 
DER
 
 pathway appears saturated, causing CPY* degradation to
be totally dependent on this novel mechanism. Substrates tar-
geted for degradation through this mechanism are ubiquiti-
nated, even in the absence of Hrd1p, by the ubiquitin ligase
Rsp5p. Only by removing both ERQC pathways is CPY* deg-
radation completely blocked. Our data call attention to the
complexity of quality control in the ER and show that mecha-
nisms in addition to the 
 
HRD
 
/
 
DER
 
 pathway are able to deliver
misfolded proteins to the proteasome for degradation.
 
Results
 
CPY* degradation continues in 
 
HRD
 
/
 
DER
 
-deficient 
cells and requires ER-Golgi transport
 
The ERQC machinery is responsible for the ERAD of mis-
folded proteins and unassembled subunits that arise in the
ER. To date, much of the analyses have focused on the in-
volvement of 
 
HRD
 
/
 
DER
 
 components in affecting the degra-
dation of ERQC substrates. Although such components
(Hrd1p/Der3p, Hrd3p, Der1p, Ubc7p, and Ubc1p) play a
major role in the degradation of ERQC substrates such as
CPY*, we have found that these substrates continue to be de-
graded at a significant rate in 
 
HRD
 
/
 
DER
 
-deficient cells. Fig.
1 A shows the degradation kinetics of wild-type cells express-
ing CPY* compared with the congenic strain lacking the
 
HRD1
 
-encoded ubiquitin ligase. As expected, the disruption
of 
 
HRD1
 
 significantly slowed the degradation rate of CPY*
compared with that in wild-type cells, but instead of com-
pletely blocking CPY* degradation, a substantial rate of
CPY* degradation still persists. Disruption of 
 
HRD3
 
, 
 
DER1,
 
or 
 
UBC7
 
 gave similar results to that shown for the 
 
hrd1
 
 
 
strain (unpublished data). Double disruptions of 
 
HRD
 
/
 
DER
 
components (
 
hrd1
 
 
 
 der1
 
 
 
) did not further stabilize CPY*
beyond that of the 
 
hrd1
 
 
 
 disruption alone (Fig. 1 A), con-
firming that these components are in the same pathway.
The finding that CPY* degradation continued in the ab-
sence of functional 
 
HRD
 
/
 
DER
 
 components raised the possi-
bility that the ERQC system possesses an additional mecha-
nism or pathway with which to achieve the degradation of
ERQC substrates. Previously, we found that anterograde ve-
sicular transport from the ER to the Golgi apparatus was re-
quired for the efficient degradation of the lumenal ERQC
substrates CPY* and PrA* (Caldwell et al., 2001). The degra-
dative rate of CPY* and PrA* was reduced when either all ve-
sicular transport from the ER was blocked through the use of
the temperature-sensitive 
 
sec12–4
 
 allele or when exit from the
ER of specific cargo proteins such as CPY* and PrA* was im-
paired by the disruption of 
 
ERV29
 
 (Caldwell et al., 2001).
Given the strong possibility of an additional degradative
mechanism/pathway, we undertook to determine if this ER-
Golgi transport step was a component of the 
 
HRD
 
/
 
DER
 
 path-
way or of an independent pathway. Strains were constructed
that were either lacking Hrd1p (
 
hrd1
 
 
 
), blocked in ER-Golgi
transport (
 
erv29
 
 
 
 or 
 
sec12–4
 
), or both (
 
hrd1
 
 
 
 erv29
 
 
 
 or 
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hrd1
 
 
 
 sec12–4
 
). Fig. 1 B shows that 
 
hrd1
 
 
 
 erv29
 
 
 
 double
mutant cells stabilize CPY* to a much greater extent than ei-
ther single mutation alone. This additive effect demonstrates
that the role of ER-Golgi transport in ERQC is independent
of the 
 
HRD
 
/
 
DER
 
 components and therefore part of a distinct
degradative pathway. The conclusion that the ERQC pos-
sesses an additional distinct pathway was further supported by
the complete stabilization of CPY* in a 
 
hrd1
 
 
 
 sec12–4
 
 double
mutant relative to either single mutant (Fig. 1 C).
 
CPY* overexpression results in 
 
HRD
 
/
 
DER
 
-independent degradation
 
In a separate project investigating the association between
CPY* and the translocon in 
 
HRD
 
/
 
DER
 
-deficient strains,
CPY* was overexpressed approximately eightfold. Surpris-
 
ingly, we observed that CPY* was now degraded with wild-
type kinetics in a 
 
hrd1
 
 
 
 strain instead of the expected
slowed degradative rate (Fig. 2 A). The wild-type degrada-
tive rate caused by overexpression of CPY* was also observed
in both 
 
der1
 
 
 
 and 
 
hrd3
 
 
 
 cells (unpublished data). This
 
HRD
 
/
 
DER
 
-independent degradation was further investi-
gated using the ERQC substrate PrA*. PrA* was overex-
pressed in both wild-type and 
 
hrd1
 
 
 
 strains, and the effect
on the rate of single copy CPY* degradation was examined.
Fig. 2 B shows that the overexpression of PrA*–HA also re-
sulted in CPY* being degraded with wild-type kinetics in a
 
hrd1
 
 
 
 strain. This suggests that this 
 
HRD
 
/
 
DER
 
-indepen-
dent degradative mechanism is not specific for CPY* and ca-
pable of recognizing and degrading a variety of lumenal
ERQC substrates.
Our working model is that the ERQC uses at least two
distinct mechanisms to identify and degrade misfolded pro-
teins from the ER: (1) the 
 
HRD
 
/
 
DER
 
 pathway using the
components Hrd1p/Der3p, Hrd3p, Der1p, and Ubc7p;
and (2) an alternative mechanism distinct from the 
 
HRD
 
/
 
DER
 
 pathway that we term the Hrd1p-independent proteol-
ysis (HIP) pathway. Upon overexpression of ERQC sub-
strates, the capacity of the 
 
HRD
 
/
 
DER
 
 pathway is likely satu-
rated, and the remaining CPY* is accommodated by the
alternative HIP mechanism. The two lines of evidence for a
 
HRD
 
/
 
DER-independent alternative pathway are as follows:
(1) the continuing degradation of ERQC substrates in
HRD/DER-deficient strains that requires ER-Golgi trans-
port; and (2) overexpression of ERQC substrates accelerates/
restores the degradative rate in HRD/DER-deficient strains.
Figure 1. CPY* degradation is completely blocked upon inhibition 
of both the HRD/DER pathway and ER-Golgi transport. hrd1  
(KHY171), hrd1  der1  (KHY237), erv29  (KHY270), erv29  
hrd1  (KHY279), sec12–4 (KHY306), sec12–4 hrd1  (KHY308), 
and wild-type (KHY163) cells were radiolabeled, chased, and CPY* 
immunoprecipitated at various times. Samples were separated by 
SDS-PAGE, visualized by fluorography, and quantitated using a 
Phosphorimager as performed previously (Hill and Cooper, 2000). 
(A) HRD/DER pathway–deficient strains (hrd1 , hrd1  der1 ) and 
wild-type cells expressing single copy levels of CPY*. (B) hrd1 , 
erv29 , hrd1  erv29 , or wild-type strains expressing single copy 
levels of CPY*. (C) hrd1 , sec12–4, hrd1  sec12–4, or wild-type 
strains expressing single copy levels of CPY* (34 C).
Figure 2. CPY* and PrA* can be degraded independently of the 
HRD/DER pathway. hrd1  and wild-type strains were radiolabeled, 
chased, and CPY* (A and B) immunoprecipitated at various times. 
Samples were analyzed as in Fig. 1. (A) Wild-type (KHY163) and 
hrd1  (KHY171) strains expressing single copy or overexpressed 
(OE) levels of CPY* (pAC453). (B) Wild-type (KHY163) and hrd1  
(KHY171) strains expressing CPY* with and without overexpressed 
PrA*–HA (pAC540) present.94 The Journal of Cell Biology | Volume 158, Number 1, 2002
To confirm that a single mechanism is responsible for both
of these observations, we formed several testable predictions
that resulted from the integration of the ER-Golgi transport
requirement and the HRD/DER pathway saturation model.
First, in otherwise wild-type cells expressing single copy lev-
els of CPY*, the absence of Erv29p should only moderately
slow the degradative rate of CPY* as the HRD/DER pathway
is functional. However, upon overexpression of CPY*, the
HRD/DER components would be saturated and the vast ma-
jority of the CPY* would be diverted to the ER-Golgi trans-
port–dependent pathway requiring Erv29p. Under these
overexpression conditions, the disruption of ERV29, which
impairs ER-Golgi transport, would now result in signifi-
cantly enhanced stabilization of CPY*. Second, the high de-
gree of CPY* stabilization in erv29  cells observed upon
CPY* overexpression will be HRD/DER-independent, and
therefore the disruption of HRD1 in such cells will have lit-
tle additional stabilizing effect. Third, the stabilization of
CPY* obtained by disabling both the HRD/DER compo-
nents and ER-Golgi trafficking through a hrd1  erv29 
double mutation should not be suppressed by overexpressing
CPY*, as the alternative pathway has already been compro-
mised by the disruption of ERV29. All three of these predic-
tions were observed upon experimentation. Fig. 3 A shows
that the degradation of single copy levels of CPY* is slowed
somewhat in an erv29  strain, and that the extent of stabili-
zation was greatly increased upon overexpression of CPY*.
As predicted, the imposition of a hrd1  mutation into the
erv29  strain overexpressing CPY* does not further stabilize
CPY* degradation (Fig. 3 B). Finally, the very strong stabili-
zation of CPY* observed in an erv29  hrd1  double mutant
expressing single copy CPY* is not suppressed upon overex-
pression of CPY* (Fig. 3 C).
In summary, overexpression of CPY* and PrA* appears to
saturate the capacity of the HRD/DER pathway and quantita-
tively shifts such substrates to the alternative pathway requir-
ing delivery to the Golgi apparatus. To confirm that CPY*
does itself transit to the Golgi apparatus, we performed se-
quential immunoprecipitations on radiolabeled hrd1  cells
overexpressing CPY*, first with anti-CPY antibodies, and
then with anti– 1,6-mannose antibodies. Fig. 3 D shows
clearly that CPY* does indeed receive  1,6 mannose addition,
which is indicative of delivery to the Golgi apparatus and con-
firms that this step is a requirement of HIP. Such a transport
requirement for efficient degradation of overexpressed ERQC
substrates might simply reflect that such substrates reach the
Golgi apparatus, are subsequently secreted from the cell, and
give the appearance of accelerated degradation or are alterna-
tively sorted to the vacuole (lysosome equivalent) for degrada-
tion. Growth media was collected from radiolabeled wild-type
and hrd1  cells overexpressing CPY* and any secreted CPY*
was immunoprecipitated. Fig. 4 B shows that neither wild-
type nor HRD/DER-deficient cells secrete detectable amounts
of CPY*. Cells lacking the VPS10-encoded receptor responsi-
ble for sorting wild-type CPY to the vacuole were included as
a control because such cells secrete large amounts of CPY
(Cooper and Stevens, 1996). Additional evidence to eliminate
the secretion possibility was provided by preventing secretory
vesicles from fusing with the plasma membrane through the
use of a temperature sensitive sec4–8 allele (Salminen and
Novick, 1987), which had no stabilizing effect on overex-
pressed CPY* degradation (unpublished data). The potential
role of the vacuole was investigated by disrupting PEP4 in a
hrd1  strain and determining the degradation rate of CPY*
expressed at both single copy and overexpressed levels. The
proteolytic activity of the vacuole is controlled by the PEP4-
encoded PrA that, when disrupted, results in the vacuole lack-
Figure 3. The inhibition of ER-Golgi transport (erv29 ) but not the 
HRD/DER pathway (hrd1 ) significantly slows the degradation of 
overexpressed (OE) CPY*. erv29  (KHY270), hrd1  (KHY171), 
hrd1  erv29  (KHY279), and wild-type (KHY163) cells were 
analyzed as in Fig. 1. (A) erv29  and wild-type strains expressing either 
single copy or overexpressed (OE) levels of CPY* (pAC453). (B) Wild-
type, hrd1 , erv29 , and hrd1  erv29  strains overexpressing (OE) 
CPY*. (C) Wild-type, hrd1 , and hrd1  erv29  strains either 
expressing single copy or overexpressed levels of CPY*. (D) hrd1  
(KHY171) cells overexpressing CPY* were radiolabeled and CPY* 
immunoprecipitated. The precipitates were reimmunoprecipitated 
with either CPY* or  1,6-mannose antibodies. ER quality control involves Rsp5p and Golgi delivery | Haynes et al. 95
ing proteolytic activity and consequential stabilization of sub-
strates degraded there (Jones et al., 1982). Fig. 4 A shows that
rendering the vacuole proteolytically inactive has no stabiliz-
ing effect on CPY* when expressed at either normal or ele-
vated levels. This result also eliminates a role for autophagocy-
tosis in HIP, as autophagocytosed substrates are degraded in
the vacuole in a PEP4-dependent manner (Baba et al., 1997).
We also investigated the degradation of CPY* in vps10  cells.
Vps10p, the CPY sorting receptor, is also capable of sorting
misfolded proteins from the trans-Golgi compartment to the
vacuole (Hong et al., 1996). However, vps10  cells failed to
stabilize overexpressed CPY* (unpublished data) and further
indicated that the alternative degradation mechanism is not
degrading substrates via delivery to the vacuole.
The HIP pathway involves the proteasome 
and ubiquitination
Cells deficient in the HRD/DER pathway remain capable of
degrading overexpressed intracellular CPY* independently
of the vacuole, which suggests that the other major intracel-
lular proteolytic activity provided by the 26S proteasome
would be responsible. Strains containing pre1 pre2 muta-
tions are deficient in 26S proteasome activity and have been
previously characterized to impair CPY* turnover (Hiller et
al., 1996). If overexpression of CPY* diverts it to the alterna-
tive pathway, then a strain deficient in this pathway should
not be capable of accelerating/restoring the CPY* degrada-
tion upon CPY* overexpression. Fig. 5 shows wild-type and
congenic  pre1 pre2 cells expressing either single copy or
overexpressed CPY*. As expected, the degradative rate of
single copy levels of CPY* is slowed considerably in the pro-
teasome-compromised strain, but overexpression of CPY*
fails to accelerate the turnover of CPY* in the pre1 pre2
strain and demonstrates that the proteasome is responsible
for degrading overexpressed CPY*.
Both the HIP and HRD/DER pathways deliver ERQC sub-
strates to the proteasome. The HRD/DER pathway achieves
this by exporting CPY* through the translocon followed by
Hrd1p-dependent ubiquitination (Plemper et al., 1997; Bays
et al., 2001), but how is overexpressed CPY* delivered to the
proteasome, and does it also involve ubiquitination? If HIP
involves ubiquitination of overexpressed CPY*, then ubiquiti-
nated forms of CPY* should be detectable in a hrd1  strain.
This was tested by sequential immunoprecipitations of radio-
labeled cells, first with anti-CPY antibodies followed by anti–
ubiquitin-HA antibodies. Fig. 6 A (lanes 1–3) shows that
CPY* in wild-type cells is heavily ubiquitinated, whereas
ubiquitinated species of CPY* still existed in the hrd1  strain,
albeit to a lesser extent. This HRD1-independent ubiquitin
signal detected was specific to CPY*, as no ubiquitin signal
was observed in a strain that lacked CPY* (prc1 ).
Rsp5p is the ubiquitin ligase of the HIP pathway
The detection of ubiquitinated CPY* in a hrd1  strain re-
quires that an additional E3 ubiquitin ligase participates in
ERQC. We screened strains deficient in known or potential
E3 enzymes, including the ER-localized DOA10 (Swanson
et al., 2001), for impaired turnover rates of overexpressed
CPY*. Ubiquitin ligases have either a RING-H2 motif or a
HECT domain (Jackson et al., 2000), and using a PSI-
BLAST homology search (Altschul et al., 1997), 31 proteins
with significant homology to the RING-H2 domains of
Hrd1p and Hrt1p were identified, whereas the 5 yeast pro-
teins with HECT domains were previously known (Hoch-
strasser, 1996). The degradative rate of overexpressed CPY*
was determined in the corresponding disruption or tempera-
ture-sensitive strains. Of the 36 potential ubiquitin ligases
screened, only the essential gene RSP5 was necessary for the
degradation of overexpressed CPY*. Fig. 6 B shows that deg-
radation of overexpressed CPY* was significantly slowed in
rsp5–2 cells at the restrictive temperature. If RSP5 represents
the ubiquitin ligase of the alternative pathway, then inacti-
vating both Rsp5p and Hrd1p should completely stabilize
single copy CPY* as both the alternative and HRD/DER
pathways would be incapacitated. This was indeed the case
as single copy CPY* is almost completely stable in a hrd1 
rsp5–2 strain (Fig. 6 C). Direct evidence that Rsp5p ubiquiti-
nates ERQC substrates was that the ubiquitinated CPY* re-
Figure 4. Overexpressed (OE) CPY* is degraded independently of 
the vacuole and is not secreted from the cell. (A) hrd1  (KHY171) 
and hrd1  pep4  (KHY265) strains were analyzed as in Fig. 1. 
hrd1  PEP4 and hrd1  pep4  strains expressing single copy or 
overexpressed levels of CPY* (pAC519). (B) hrd1  (KHY171) and 
wild-type (KHY163) cells overexpressing (OE) CPY* and vps10  
(AACY9) cells expressing CPY were radiolabeled, chased, and CPY* 
or CPY was immunoprecipitated from intracellular (I) and extracellular 
(E) fractions as described previously (Cooper and Stevens, 1996). 
Samples were visualized by fluorography.
Figure 5. The proteasome is responsible for the degradation of 
overexpressed (OE) CPY*. pre1 pre2 (KHY293) and wild-type 
(KHY292) strains expressing single copy (pAC446) or overexpressed 
levels of CPY* (pAC519) were analyzed as in Fig. 1.96 The Journal of Cell Biology | Volume 158, Number 1, 2002
maining in a hrd1  strain is not observed in the rsp5–2
hrd1  double mutant (Fig. 6 A, lanes 3–5).
To confirm that Rsp5p is a component of the HIP pathway
instead of a potential third degradative pathway, we intro-
duced the rsp5–2 mutation into a strain deficient for the HIP
pathway (erv29 ). The stabilization of CPY* in an erv29 
rsp5–2 double mutant was found to be no greater than either
of the single mutants, indicating that Rsp5p is indeed a com-
ponent of the HIP pathway (unpublished data). Furthermore,
overexpression of CPY* in a hrd1  rsp5–2 strain does not
suppress stabilization of CPY* (unpublished data).
The RING-H2 ubiquitin ligase Hrd1p has been demon-
strated to use the ubiquitin-conjugating enzymes Ubc7p and
Ubc1p (Friedlander et al., 2000; Bays et al., 2001) in the
HRD/DER pathway. In contrast to Hrd1p, Rsp5p is a
HECT domain ubiquitin ligase, and previous work has indi-
cated that Rsp5p uses the ubiquitin-conjugating enzymes
Ubc4p and Ubc5p (Gitan and Eide, 2000). If Ubc4p and
Ubc5p act in concert with Rsp5p to mediate the degradation
of ERQC substrates by the HIP pathway, then the absence
of both Ubc4p and Ubc5p should impair the degradation of
that substrate. The degradative rate of overexpressed CPY*
was examined in both wild-type and ubc4  ubc5  cells,
where it was found that the absence of Ubc4p and Ubc5p
significantly slowed the degradation of CPY* (Fig. 6 D).
The HIP pathway is also capable of degrading integral 
membrane ERQC substrates
The finding that the ERQC possesses an alternative degrada-
tive pathway capable of degrading lumenal ERQC substrates
raised the issue of whether integral membrane ERQC pro-
teins such as Sec61–2p might also be an alternative pathway
Figure 6. Rsp5p is the ubiquitin ligase of the HIP pathway and is 
responsible for the ubiquitination of CPY* in HRD/DER pathway–
deficient cells. (A) Ubiquitination of CPY* in wild-type (lane 1), 
prc1  hrd1  (lane 2), hrd1  (lane 3), rsp5–2 (lane 4), and hrd1  
rsp5–2 (lane 5) cells was assayed by radiolabeling at 37 C followed 
by sequential immunoprecipitations first with anti-CPY antibodies 
and then with anti–ubiquitin-HA antibodies. (B and C) rsp5–2 
(KHY355), hrd1  (KHY171), hrd1  rsp5–2 (KHY359), and 
wild-type (KHY163) strains were radiolabeled, chased (at 37 C), and 
CPY* immunoprecipitated at various times. Samples were analyzed 
as in Fig. 1. (B) Wild-type and rsp5–2 cells overexpressing (OE) 
CPY* (pAC453). (C) Wild-type, hrd1 , rsp5–2, and hrd1  rsp5–2 
expressing single copy levels of CPY*. (D) Wild-type (RH448) and 
ubc4  ubc5  (RH3097) overexpressing (OE) CPY*–HA were 
radiolabeled (at 30 C), chased, and CPY* immunoprecipitated.
Figure 7. The integral membrane ERQC substrate Sec61–2p-HA 
can also be degraded by the HIP pathway. hrd1  (KHY171), rsp5–2 
(KHY355), hrd1  rsp5–2 (KHY359), and wild-type (KHY163) cells 
were radiolabeled at 37 C (A) and 30 C (B), chased, Sec61–2p-HA 
immunoprecipitated at various times, and analyzed as in Fig. 1. 
(A) Wild-type, hrd1 , rsp5–2, and hrd1  rsp5–2 expressing 
Sec61–2p-HA (pAC460; Caldwell et al., 2001). (B) prc1  (KHY298) 
and prc1  hrd1  (KHY299) cells, in the absence of CPY*, expressing 
Sec61–2p-HA (pAC460) and wild-type (KHY163) and hrd1  
(KHY171) in the presence of overexpressed (OE) CPY* expressing 
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substrate. The fact that Sec61–2p is not stabilized in a strain
lacking Erv29p (Caldwell et al., 2001) does not exclude
Sec61–2 from the alternative pathway because, Erv29p ap-
pears to act as a cargo receptor for a specific subset of ER lu-
menal proteins that would have no effect on integral mem-
brane proteins. Sec61–2p seems likely to be a substrate of an
alternative pathway as, analogous to CPY* in Fig. 1 A, the
disabling of the HRD/DER pathway reduced, but did not
abolish, the degradation of Sec61–2p (Fig. 7 A). Wild-type
cells, hrd1 , rsp5–2, or hrd1  rsp5–2 double mutants ex-
pressing Sec61–2p were radiolabeled at the restrictive temper-
ature and the degradative kinetics of Sec61–2p were exam-
ined (Fig. 7 A). Even when the HRD/DER pathway is
functional, Rsp5p contributes to the degradation of Sec61–
2p as shown by the retarded degradative kinetics in the rsp5–2
strain. Second, the inactivation of Rsp5p in cells lacking
HRD/DER components (rsp5–2 hrd1 ) further stabilized
Sec61–2p. The findings that Sec61–2p is not fully stabilized
in  HRD/DER- deficient cells and that inactivation of the
Rsp5p further stabilizes Sec61–2p suggest that integral mem-
brane ERQC substrates can be degraded by the HIP pathway.
The ability of the alternative pathway to degrade Sec61–2p
was further demonstrated by overexpressing CPY* in hrd1 
cells also expressing Sec61–2p with the result that the re-
tarded Sec61–2p degradation kinetics seen in hrd1  cells was
accelerated to those of a wild-type cell (Fig. 7 B).
The UPR regulates the HIP pathway
Of the many genes transcriptionally up-regulated by the
UPR during ER stress (Travers et al., 2000), half have no
known function attributed to them (Fewell et al., 2001). It
is conceivable that components of the HIP pathway, like
those of the HRD/DER pathway (Friedlander et al., 2000),
may also be up-regulated during times of stress and therefore
would be under UPR transcriptional control. If so, then dis-
abling the UPR pathway would diminish or inactivate the
HIP pathway. To test this possibility, CPY* was expressed
either at single copy or overexpressed levels in wild-type cells
or cells disrupted for IRE1. The absence of Ire1p had little
significant effect on the degradation of single copy CPY*
(Fig. 8), which is consistent with that previously reported
(Friedlander et al., 2000), presumably because in the ab-
sence of the UPR the capacity of the HRD/DER pathway is
sufficient to cope with single copy levels of CPY*. Overex-
pression of CPY* in an ire1  strain significantly slowed the
turnover kinetics of CPY* (Fig. 8), which demonstrates that
the HIP pathway requires a functional UPR.
Discussion
ERQC substrates continue to be degraded in the absence of
a functional HRD/DER pathway using a newly identified al-
ternative mechanism that requires ER-Golgi vesicular trans-
port of substrates and the ubiquitin ligase Rsp5p before pro-
teasomal degradation. This alternative system is distinct
from the HRD/DER pathway, but together the two com-
prise the ERQC degradative capacity because only by dis-
abling both pathways is degradation completely blocked.
We propose the acronym HIP for the alternative mecha-
nism. Overexpression of ERQC substrates appears to satu-
rate the capacity of the HRD/DER pathway, resulting in the
degradation of ERQC substrates to be completely depen-
dent on the HIP pathway.
The ubiquitin ligase Rsp5p is a component of the HIP
pathway and together with Hrd1p is responsible for the
ubiquitination of CPY*. Only by inactivating both Rsp5p
and Hrd1p does CPY* fail to be ubiquitinated and remains
completely stable. Rsp5p-dependent ubiquitination involves
the ubiquitin-conjugating enzymes Ubc4p and Ubc5p (Gi-
tan and Eide, 2000), and these enzymes were also required
by the HIP pathway to degrade overexpressed CPY*. In ad-
dition to its role in ERQC, Rsp5p is responsible for mediat-
ing ubiquitin-dependent protein sorting and trafficking
within the secretory pathway. The ubiquitination of plasma
membrane proteins by Rsp5p results in their internalization
and subsequent transport to the vacuole for degradation
(Galan et al., 1996; Hicke and Riezman, 1996). Rsp5p, act-
ing in concert with Bul1p and Bul2p, can also ubiquitinate
proteins such as Gap1p to direct them from the trans-Golgi
compartment to the vacuole for degradation (Helliwell et
al., 2001). However, the role of Rsp5p in ERQC is distinct
from that involving vacuolar sorting, as the HIP pathway is
independent of vacuolar proteases and instead utilizes the
proteasome. Furthermore, the disruption of both BUL1 and
BUL2 has no effect on the degradation rate of CPY* (un-
published data).
Examination of the mechanisms used by mammalian cells
to degrade ERQC substrates suggests extensive overlap with
the HIP pathway described here. This similarity includes the
observation of the following ERQC substrates in post-ER
compartments (ER-Golgi intermediate compartment and/or
Golgi subcompartments): unassembled MHC class I mole-
cules (Hsu et al., 1991), misfolded G protein of vesicular sto-
matitis virus (Hammond and Helenius, 1994), mutant forms
of sucrase-isomaltase and lysosomal  -glucosidase (Moolenaar
et al., 1997), and precursors of human asialoglycoprotein re-
ceptor H2a (Kamhi-Nesher et al., 2001). The soluble secre-
tory form of IgM molecules in differentiated B lymphocytes is
degraded intracellularly in a manner completely dependent on
transport to a post-ER compartment (Winitz et al., 1996),
and truncated versions of CFTR reach the Golgi apparatus
before degradation by the proteasome (Benharouga et al.,
2001). Further evidence suggesting the involvement of post-
Figure 8. The UPR is required for efficient degradation of 
overexpressed (OE) CPY*. ire1  (KHY280) and wild-type 
(KHY163) cells expressing single copy and overexpressed levels 
(pAC453) of CPY* were analyzed as in Fig. 1.98 The Journal of Cell Biology | Volume 158, Number 1, 2002
ER compartment(s) is that some ERQC components are
themselves found in post-ER locations: UDP-glucose:glyco-
protein glucosyltransferase (UGGT), an important ERQC
glycoprotein folding sensor, is found in post-ER vesicles
(Zuber et al., 2001), whereas endo- -mannosidase has been
implicated in quality control and was localized to the cis/me-
dial-Golgi apparatus (Zuber et al., 2000).
How far through the secretory pathway do ERQC sub-
strates such as CPY* progress and what function would deliv-
ery of ERQC substrates to the Golgi apparatus serve? CPY*
in either DER1-deficient cells (Knop et al., 1996) or those
lacking an ER-localized proposed ERQC lectin (mnl1 /
htm1 ) (Jakob et al., 2001; Nakatsukasa et al., 2001) re-
ceived  1,6-mannose addition but not  1,3-mannose addi-
tion, indicating that CPY* reached the cis-Golgi but not the
trans-Golgi compartment (Brigance et al., 2000). Similarly,
we have also found that CPY* is delivered to the cis-Golgi
compartment when overexpressed in hrd1  cells as evi-
denced by the addition of  1,6-mannose. A recent report has
shown that a heterologously expressed fusion ERQC sub-
strate Kar2 hemagglutinin neuraminidase receives O-linked
glycosylation indicative of it reaching the yeast cis/medial-
Golgi apparatus, whereas both KHN and CPY* can be
found in in vitro ER-derived COPII vesicles (Vashist et al.,
2001). Vashist et al. (2001) concluded that all the KHN is
delivered to the Golgi apparatus, and then is returned to the
ER where it is exported to the cytosol and likely ubiquiti-
nated by Hrd1p. However, we suggest another possibility
wherein KHN (much like CPY*) is degraded via two distinct
pathways (HIP and HRD/DER), in which a portion of KHN
is retained in the ER and is exported and ubiquitinated by
Hrd1p while the remaining KHN is transported to the Golgi
apparatus and eventually ubiquitinated by Rsp5p.
After transportation to the Golgi apparatus, CPY* must
then be exported from within the secretory pathway to the
cytosol to be accessible to the cytosolically located Rsp5p.
Therefore CPY* is likely returned from the Golgi apparatus
to the ER where it is exported to the cytosol, presumably
through the translocon, and subsequently ubiquitinated by
Rsp5p before proteasomal degradation. A highly speculative
alternative model involves the export of CPY* directly from
the cis-Golgi compartment to the cytosol by an unidentified
mechanism before ubiquitination by Rsp5p. These two pos-
sibilities are presented in the model shown in Fig. 9. Unfor-
tunately, the broad subcellular distribution of Rsp5p pro-
vides no indication as to which model is correct (Gajewska
et al., 2001). Rsp5p can presumably associate with both the
Golgi apparatus to mediate Gap1p sorting (Helliwell et al.,
2001) and the ER, as evidenced by its ubiquitination of
the nuclear membrane/ER-restrained transcription factor
Spt23p (Hoppe et al., 2000). Although ERQC substrates
are likely returned to the ER from the Golgi apparatus, such
a requirement has yet to be definitely demonstrated. The use
of Golgi to ER retrograde trafficking mutants is problematic
as those mutants tested also show defects in forward trans-
port over the time course required for the degradation exper-
iments (unpublished data). The rationale for delivering
ERQC substrates to the Golgi apparatus may be either to (a)
access a mechanism responsible for exporting it directly from
the Golgi apparatus to the cytosol, or (b) to receive a Golgi
apparatus-based modification that signals either its efficient
translocation to the cytosol on its return to the ER or its effi-
cient ubiquitination by Rsp5p on its retrotranslocation from
the ER to the cytosol. We favor an alternative model in
which ERQC substrates are not actively targeted to the
Golgi apparatus, but instead are inadequately retained in the
ER by the relevant components of the HRD/DER pathway
and are transported to the Golgi apparatus. The insufficient
ER retention may be because certain individual ERQC sub-
strates interact poorly with the HRD/DER components or
due to saturation of this pathway. Therefore the cis-Golgi
apparatus may act as a quality control catchment system to
capture ERQC substrates that have “escaped” the ER before
returning them by retrograde transport to the ER.
The existence of an alternative degradative system has pre-
viously been proposed by us (Hill and Cooper, 2000) and
Figure 9. Summary: ERQC consists of two 
degradative mechanisms, the HIP and the HRD/
DER pathway. Substrates destined for the HRD/
DER pathway are recognized as being misfolded or 
unassembled, and are retained in the ER before being 
retrotranslocated through the translocon to the 
cytosol where the Hrd3p-regulated ubiquitin ligase 
(Hrd1p) attaches ubiquitin to the substrate and it is 
subsequently degraded by the 26S proteasome. 
The mechanism described here (HIP) eliminates 
misfolded proteins from the ER in a manner that 
requires vesicular transport from the ER to the 
Golgi apparatus involving Sec12p and the putative 
CPY* cargo receptor, Erv29p. Once in the cis-Golgi 
compartment, CPY* is modified by  1,6-mannose 
addition before ubiquitination by the ubiquitin 
ligase Rsp5p and subsequent degradation by the 
proteasome. Where the misfolded protein enters 
the cytosol and is exposed to Rsp5p is not clear, 
however, two locations seem possible: (1) it may 
enter the cytosol from the Golgi apparatus by an 
unknown mechanism, or (2) it may be transported 
back to the ER where it presumably would enter 
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others (Friedlander et al., 2000) to explain either the contin-
ued degradation of ERQC substrates in HRD/DER-defi-
cient cells or the surprising finding that cells deficient for the
HRD/DER pathway display no growth defects even when
expressing misfolded proteins in the ER. However, double
mutants lacking both the UPR and HRD/DER pathways
display significantly impaired growth phenotypes that are
further exacerbated by ER stress (Friedlander et al., 2000;
unpublished data). These observations are consistent with
our findings that the HIP pathway is likely under UPR con-
trol such that the hrd1  ire1  mutant is deprived of both of
its options in dealing with ER stress. Consistent with this
model of UPR-regulated HIP is the identification of a num-
ber of genes under UPR transcriptional regulation that are
involved in ER to Golgi vesicular transport and therefore
likely necessary for the HIP pathway (Travers et al., 2000).
The importance of preventing both the aggregation of
misfolded proteins in the ER and the transport of these pro-
teins to the cell surface is underscored by the fact that the
cell uses at least two distinct mechanisms to effect their deg-
radation. However, this apparent redundancy raises the
question of why one would observe any stabilization of
ERQC substrates in HRD/DER-deficient cells while the
HIP pathway is functional. It is possible that the two sys-
tems complement each other, with the HRD/DER pathway
comprising a low capacity system for contending with the
nominal loads of misfolded proteins accruing in the ER un-
der optimal growth conditions. The HIP pathway might act
as a high capacity mechanism that is up-regulated, poten-
tially by the UPR, to accommodate increased levels of
ERQC substrates.
In summary, we have identified an HRD/DER-indepen-
dent degradation mechanism in which ER-Golgi trafficking
and Rsp5p-dependent ubiquitination is required before deg-
radation by the proteasome. Further work will identify the
purpose of delivering ERQC substrates to the Golgi appara-
tus, where in the cell ERQC substrate ubiquitination by
Rsp5p occurs, and how such substrates gain access to the
Rsp5p in the cytosol.
Materials and methods
Plasmids, media, and strain construction
Media were prepared as described previously (Hill and Stevens, 1994). To
introduce prc1 ::KAN, ubc7 ::KAN, ire1 ::KAN, and hrd1 ::KAN al-
leles into strains, oligonucleotides flanking the disrupted allele were used to
amplify the allele from strains of the S. cerevisiae Genome Deletion Project
(Research Genetics). The product was then transformed into a strain with
subsequent selection on YEPD media containing 200  g/ml G418. Disrup-
tions were confirmed by PCR analysis on genomic DNA using oligonucle-
otides flanking each disrupted locus. WCG4a and WCGL-11/21a (pro-
vided by Dieter Wolf, Universitaet Stuttgart, Stuttgart, Germany) were
transformed with the prc1 ::KAN allele to make strains KHY292 and
KHY293; ire1 ::KAN was transformed into KHY163 to create KHY280,
ubc7 ::KAN was transformed into KHY163 to make KHY313; and hrd1 ::
KAN was transformed into KHY355 to create KHY359.
KHY163 was constructed as described previously (Caldwell et al.,
2001). KHY171 was created by repairing the vma22  locus of KHY140
(Hill and Cooper, 2000). The prc1 ::KAN allele was amplified by PCR and
inserted into pTOPO 2.1 (Invitrogen) to create pAC550. A 0.9-kb ClaI-SalI
fragment from pAC550 was replaced with the HIS3-containing ClaI-SalI
fragment from pJJ217 to create pAC556. The prc1 ::HIS3 allele from
pAC556 was amplified by and transformed into KHY163 and KHY171,
creating strains KHY298 and KHY299, respectively. The disruption was
confirmed by PCR and Western blot (Caldwell et al., 2001). The pep4 ::
TRP1 allele from SacI-XhoI–digested pLS1–10 (provided by Dr. Steven
Nothwehr, University of Missouri, Columbia, MO) was introduced into
KHY171 to create KHY265. The ubc6 ::HIS3 allele was amplified by from
RH3140 (provided by Dr. Linda Hicke, Northwestern University, Evan-
ston, IL), and transformed into KHY313, creating KHY333.
The hrd1 ::TRP1 allele was constructed by inserting a TRP1-containing
BglII-NsiI fragment from pJJ248 into BglII-NsiI–digested pAC370 (Hill and
Cooper, 2000) creating pAC401. The hrd1 ::TRP1 allele from DraI-digested
pAC401 was introduced into KHY127 (Hill and Cooper, 2000) and KHY270
(Caldwell et al., 2001) to create strains KHY158 and KHY279, respectively.
KHY237 was created by repairing the vma22  locus in KHY158.
To introduce the sec12–4 allele and create KHY306 and KHY308, SalI-
digested pAC559, was transformed into KHY163 and KHY171, and Ura
 
prototrophs were placed on 5-FOA. Ura
  colonies were screened by fail-
ure to grow at 38 C. pAC559 was created by ligating a sec12–4 containing
3.4-kb XhoI-XbaI from pSHf2–1 (provided by Dr. Akihiko Nakano, RIKEN,
Wako, Saitama, Japan) into XhoI-SpeI-digested pRS306. The rsp5–2 allele
was introduced by transforming KHY163 with StuI-digested pKM017 (pro-
vided by Dr. Stefan Jentsch, Max Plank Institute of Biochemistry, Martinsried,
Germany). RSP5 was then deleted by transforming the rsp5 ::HIS3-con-
taining fragment from SacI-SphI–digested pKM017.
Strains deleted for potential ubiquitin ligase genes were transformed
with pAC578, radiolabeled, and CPY–HA was immunoprecipitated at vari-
ous times (Hill and Cooper, 2000). Potential RING-H2–containing proteins
were as follows: YFL010C, YMR075C-A, YKR073C, YKL034W, YDR128W,
YOL138C,  YCR066W,  YHL010C,  YOL054W,  YLR247C,  YLR024C,
YGR184C,  YHR115C,  YDR265W,  YDR266C,  YOR191W,  YOR027W,
YLR427W, YMR247C,  YDR143C,  YLR032W,  YPR093C,  YNL116W,
YBR114W,  YLR148W,  YER068W,  YIL030C ( DOA10/SSM4),  YER116C,
YDL074C,  YBR062C, and YDL013W; and strains deleted/temperature
sensitive allele for HECT domain–containing proteins are YJR036C,
YDR457W, YKL010C, YGL141W, and YER125W.
pAC453 and pAC519 are 2- m plasmids and pAC446 is a CEN plasmid
in which a prc1–1-containing 2.8-kb SacI-SalI fragment from pAC356 (Hill
and Cooper, 2000) was ligated into the SacI-SalI sites of pTV3,YEp352,
and pRS315, respectively. pAC578 was created by ligating a CPY–3XHA–
containing 4.3-kb SacI-XhoI fragment from pBG15 (provided by Dr. Scott
Moye-Rowley, University of Iowa, Iowa City, IO) into SacI-SalI–digested
YEp352. pAC540 is a 2- m plasmid in which the 1.9-kb SacI-BglII frag-
ment containing PrA–3XHA from pAC535 (Caldwell et al., 2001) was li-
gated in SacI-BamHI–digested YEp352.
Radiolabeling, immunoprecipitation, and antibodies
Radiolabeling and immunoprecipitation were performed as described pre-
viously (Hill and Cooper, 2000). Samples were resolved by SDS-PAGE, the
gels were fixed, dried, and exposed either to a phosphor cassette (Molecu-
lar Dynamics) or to X-ray film. Quantification of gels was performed as de-
scribed previously (Hill and Cooper, 2000).
Ubiquitin experiment
Yeast strains overexpressing HA-tagged ubiquitin from the CUP1 promoter
(YEp112, provided by Dr. Mark Hochstrasser, Yale University, New Ha-
ven, CT) were grown overnight in 0.2% oleic acid minimal media contain-
ing 150  M CuSO4. Cells were radiolabeled, spheroplasted, and lysed in
buffer containing 10 mM NEM. Immunoprecipitation of CPY* was as de-
scribed previously (Hill and Cooper, 2000), except with subsaturating
amounts of antibody. A sequential immunoprecipitation was performed
with HA antibodies. Samples were loaded on a 10% SDS-PAGE.
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